666.HK

AIM Vaccine Announces Proposed Listing on the Main Board of SEHK

Retrieved on: 
星期五, 九月 23, 2022
Global, Safety, IPV, Efficiency, CIC, National Medical Products Administration, RNA transfection, HFRS, HAV, Goldman Sachs, Industry, China International Capital Corporation, Stock exchange, Clinical trial, Mumps, Technology, CDC, Meningococcal disease, Vaccine, US, HPV, Research, International, SEHK, COVID-19, Food, Company, Rabies, NDA, Omicron, Science, Exploration, NMPA, Globe, COVID-19 vaccine, AIM, Culture, L.L.C, National, CTA, Honesty, HBV, CMOS, Public health, Coronavirus, Record, Marketing, GMP, Motherboard, Health, The Group, Program, 2000 Simpsonwood CDC conference, Infection, Pharmaceutical industry, Property management, PRC, Group, Limited

According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.

Key Points: 
  • According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.
  • AIM Vaccine currently commercializes eight vaccine products against six disease areas, of which the HBV vaccines and human rabies vaccine are its market-leading key commercialized vaccine products.
  • AIM Vaccine acquired Rong'an Bio, AIM Honesty, AIM Kanghuai and AIM Weixin between 2015 and 2017, together with their vaccine products against human rabies, HBV, HAV, mumps and HFRS.
  • AIM Vaccine has leading scientists joining or collaborating with AIM Vaccine to support the Group's vaccine development and manufacturing.